

Jeffrey C Allen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2374236/publications.pdf>

Version: 2024-02-01

45
papers

3,320
citations

331670

21
h-index

345221

36
g-index

47
all docs

47
docs citations

47
times ranked

4063
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28753.	1.5	13
2	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	1.5	9
3	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	1.5	17
4	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54
5	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29172.	1.5	3
6	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591.	4.1	11
7	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. <i>Neurology</i> , 2021, 97, S99-S110.	1.1	2
8	Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 880-890.	1.7	9
9	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	1.2	45
10	Diffuse midline glioma with novel, potentially targetable, FGFR2-VPS35 fusion. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005660.	1.2	5
11	NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii419-iii419.	1.2	4
12	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	1.2	0
13	CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii45.	1.2	1
14	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	1.2	0
15	Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the head-start and II clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 140, 717-725.	2.9	5
16	Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. <i>Journal of Neuro-Oncology</i> , 2018, 139, 749-755.	2.9	28
17	Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2056-2056.	1.6	2
18	LG-67MIDBRAIN GLIOMAS: A LARGE SERIES OF CLINICALLY AND RADIOGRAPHICALLY HETEROGENEOUS TUMORS. <i>Neuro-Oncology</i> , 2016, 18, iii94.2-iii94.	1.2	0

#	ARTICLE	IF	CITATIONS
19	TB-27SUBGROUP-SPECIFIC OUTCOMES OF CHILDREN WITH MALIGNANT CHILDHOOD BRAIN TUMORS TREATED WITH AN IRRADIATION-SPARING PROTOCOL. <i>Neuro-Oncology</i> , 2016, 18, iii173.3-iii173.	1.2	0
20	NIMG-76. MIDBRAIN GLIOMAS: A LARGE SERIES THAT IDENTIFIES FEATURES CORRESPONDING WITH OUTCOME. <i>Neuro-Oncology</i> , 2016, 18, vi141-vi141.	1.2	0
21	Outcome of young children with high-grade glioma treated with irradiation avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1806-1813.	1.5	29
22	EPT-21EFFICACY OF EVEROLIMUS IN PEDIATRIC BRAIN TUMORS: A SINGLE-INSTITUTION PATIENT SERIES. <i>Neuro-Oncology</i> , 2016, 18, iii28.3-iii28.	1.2	1
23	The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 453-459.	1.3	4
24	Differentiating high and low grade pediatric brain tumors using diffusional kurtosis imaging. <i>Journal of Pediatric Neuroradiology</i> , 2015, 02, 301-305.	0.1	0
25	Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. <i>Pediatric Blood and Cancer</i> , 2015, 62, 317-321.	1.5	20
26	Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiation: Findings from the Third International Central Nervous System (CNS) Germ Cell Tumor (GCT) Study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1920-1924.	1.5	10
27	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
28	GENO-20NOVEL CANDIDATE ONCOGENIC DRIVERS IN PINEOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v95.4-v96.	1.2	0
29	The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients. <i>Cancer Research</i> , 2015, 75, 16-21.	0.9	56
30	Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2464-2471.	1.6	136
31	Management of CNS germinoma. <i>CNS Oncology</i> , 2015, 4, 273-279.	3.0	54
32	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	1.2	44
33	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	1.2	175
34	Functional outcome measures for NF1-associated optic pathway glioma clinical trials. <i>Neurology</i> , 2013, 81, S15-24.	1.1	103
35	Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1180-1182.	1.5	63
36	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1006-1011.	0.8	47

#	ARTICLE	IF	CITATIONS
37	Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus. <i>Neuro-Oncology</i> , 2004, 6, 127-133.	1.2	45
38	Acquired aphasia in children after surgical resection of left thalamic tumors. <i>Developmental Medicine and Child Neurology</i> , 2000, 42, 580-590.	2.1	0
39	Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 832-832.	1.6	674
40	A Phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. <i>Cancer</i> , 1999, 86, 1064-1069.	4.1	64
41	Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/Primitive neuroectodermal tumors. <i>Cancer</i> , 1997, 80, 798-804.	4.1	91
42	A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. <i>Cancer</i> , 1994, 74, 940-944.	4.1	142
43	Hyperfractionated radiotherapy for children with brainstem gliomas: A pilot study using 7,200 cGy. <i>Annals of Neurology</i> , 1990, 27, 167-173.	5.3	78
44	Supratentorial malignant gliomas in childhood: A review of fifty cases. <i>Annals of Neurology</i> , 1987, 22, 355-364.	5.3	93
45	Alphafetoprotein and human chorionic gonadotropin determination in cerebrospinal fluid. <i>Journal of Neurosurgery</i> , 1979, 51, 368-374.	1.6	185